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WORK PERFORMANCE LIMITATIONS POST ANASTROZOLE TREATMENT FOR 
WOMEN WITH BREAST CANCER 
Taylor Popelas, MS 
University of Pittsburgh, 2014 
Due to early diagnosis and advancements in breast cancer treatments, an increasing number of 
women are living longer after treatment. Conversely, many women’s experiences of extended 
life involve enduring long-term effects of breast cancer treatments possibly including pain, 
fatigue, decreased energy, sensory, and motor function, lymphedema, cognitive impairments, 
osteoporosis, nausea, and sleeping difficulties (American Cancer Society, 2013; Brach et al., 
2004; Jenkins, Shilling, Fallowfield, Howell, & Hutton, 2004; Pullens, De Vries, & Roukema, 
2010).  Aromatase inhibitors, including anastrozole, have proven efficacy for adjuvant therapy 
in postmenopausal women with breast cancer (Nabholtz, 2008; Rinaldi, 2013). Adjuvant therapy 
may have negative effects on cognitive functioning (Bender et. al., 2007; Nattinger et al., 2013). 
Cognitive, physical, and affective impairments contribute to the likelihood of increased work 
problems.  Largely, the condition, treatments, and consequential effects may alter body 
functions/structures, activities, and community participation. In theory, anastrozole treatment 
may increase the likelihood of work problems. 
Work after a cancer diagnosis is highly desirable for individuals on a person, social, and 
economic level, ultimately contributing to quality of life, dignity, self-esteem, and purpose 
(Steiner, Cavender, Main, & Bradley, 2004). Women with breast cancer commonly report 
work-related concerns including job loss, demotion, unwanted changes in tasks, problems with 
the employer/co-workers, personal changes in attitudes to work and diminished physical capacity 
(Brisson, Dubois, Fraser, Lauzier, & Maunsell, 1999). The purpose of this study was to examine 
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the effects of the anastrozole breast cancer treatment, as it relates to the individuals’ abilities to 
function at work.  Through critical analysis of data from the Anastrozole Use In Menopausal 
Women (AIM) study, this study found that overall, the anastrozole group reported more work 
problems than the control group overtime.  Pain emerged as a confounding variable that supports 
reason for further investigation of the effects and role of pain due to breast cancer and/or 
treatment, specifically as it pertains to work performance. Knowing that more individuals with 
breast cancer are surviving and are continuing to work or returning to work, additionally 
considering that treatment effects and residual symptoms are often present, this population 
likely would benefit from vocational rehabilitation support and services.  
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1.0  INTRODUCTION 
1.1 BREAST CANCER 
Accounting for approximately 29% of newly diagnosed cancers in U.S. women, breast cancer is 
the most pervasive, aside from skin cancers.  In 2013, there were an estimated 232,340 new cases 
of breast cancer diagnosed in U.S. women, resulting in approximately 39,620 deaths (American 
Cancer Society, 2013).  Among the physical and emotional challenges that women with breast 
cancer and their families encounter, are an overwhelming number of decisions that they and their 
health care team confront.  Screening the available therapeutic programs and treatment options 
are among these decisions.  Multiple treatment options are offered for patients with different 
types of breast cancer and volumes of information are available to make the best treatment 
choices for the particular diagnosis.  As incidence rates typically increase with age, 
approximately 79% of new cases of breast cancer occur in women 50 years of age and older 
(American Cancer Society, 2013).  Due to early diagnosis and advancements in breast cancer 
treatments, including adjuvant treatments, an increasing number of women are living longer. 
Conversely, many women’s experiences of extended life include enduring long-term effects of 
breast cancer treatments.  Effects may include pain, limited range of motion, fatigue, decreased 
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energy, decreased sensory and motor function, lymphedema, cognitive impairments, 
osteoporosis, musculoskeletal symptoms, nausea, hair loss, and sleeping difficulties (American 
Cancer Society, 2013; Brach et al., 2004; Jenkin, Shilling, Fallowfield, Howell, Hutton, Hutton, 
2004; Pullens, De Vries, and Roukema, 2010).  Secondary effects may compound or arise from 
receiving treatments.  Symptoms and experiences such as anxiety, depression, fear of recurrence 
or death, self-concept issues, social isolation, disruptions in family and sexual relationships, and 
decreased independence are commonly reported to occur (Brach et al., 2004; Schilder et al., 
2012).  Overall, the condition may alter body functions, structure, activities, community 
participation, and environmental factors.  
An insufficient number of studies have directly addressed the activity limitations and 
participation restrictions faced by women with breast cancer (Karki, Simonen, Malkia, & Selfe, 
2005).  As affects of breast cancer and treatments have been well documented, it is imperative 
that a systematic framework be constructed for accurately defining and assessing clearly 
objectified functional limitations that impact activity and participation.  The International 
Classification of Functioning, Disability and Health (ICF), published by the World Health 
Organization, is an international classification system and currently the standard for 
communicating health and health-related states through a common language over multiple 
contexts (World Health Organization, 2001).  Core sets of functioning are described for 
numerous health conditions to distinctly label functional limitations that may present for an 
individual with that condition, in addition to environmental and personal factors that contribute 
to the overall effect of the limitations.   
Within the past 10 years, a team of international healthcare experts identified and 
developed a core set of functional limitations for individuals with breast cancer, based on the ICF 
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framework (Brach et al., 2004).  This was the first comprehensive list developed according to the 
standards of the ICF.  ICF core sets for breast cancer intend to direct proper identification and 
definition of problems with daily functioning and guide multidisciplinary treatment (Brach et. 
al., 2004).  Not until 2013 was the core sets validated by the perspective of women who had the 
condition.  Qualitative research, conducted by Cooney, Galvin, Connolly, and Stokes (2013), 
exploring the perspective of women who have undergone breast cancer treatment strongly 
supported the validation of the ICF core set for breast cancer.  Furthermore, the women 
identified additional ICF categories that were not included in the core sets.  Reevaluation of the 
current core sets, potential addition of newly identified limitations, and continual modifications 
are essential to maintain the efficacy of the ICF core sets for breast cancer, in addition to 
facilitating proper treatment and promoting optimal functioning for women with breast cancer. 
1.2 BREAST CANCER TREATMENTS 
The current standard treatments for breast cancer may include surgery, radiation therapy, 
chemotherapy, hormone therapy, targeted therapy, and sentinel lymph node biopsy followed by 
surgery, depending on disease characteristics (Hartmann, 2012).  Treatments are recommended 
based on numerous factors, one of the most important being the stage of breast cancer.  Staging 
determines the extent to which the cancer has spread at the time of diagnosis.  Through physical 
exams, scans, imaging, and tests, the cancer is evaluated and identified as being invasive or non-
invasive, additionally considering if the cancer has spread to other parts of the body, the tumor 
size, and the number of lymph nodes involved.  This process helps the clinical team determine 
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the stage of cancer.  A most common staging system for breast cancer is the American Joint 
Committee on Cancer (AJCC) TNM system.  Stage grouping based on the TNM system 
generates levels expressed with Roman numerals, with stage I being the least advanced stage to 
stage IV being the most advanced stage (American Cancer Society, 2013). 
The hormone estrogen is a main contributor to the development of breast cancer.  
Hormonal therapies were designed to utilize endocrine agents in reducing the synthesis of 
estrogen or blocking the estrogen from binding with the breast tumor receptor site.  For decades, 
the gold standard of hormonal treatment of early stage breast cancer in postmenopausal women 
has been tamoxifen. As resistance to tamoxifen developed, adjuvant therapies were created in the 
mid 1990’s, to supplement or add to hormonal treatment options.  Among these newer 
developments was an aromatase inhibitor (AI), anastrozole.  The enzyme aromatase acts as a 
catalyst in the conversion of androgens to estrogens and provides as the principle factor in the 
synthesis of estrogen in postmenopausal women (Buzdar, 2006).  Inhibiting aromatase is one 
approach to breast cancer prevention and treatment.  Aromatase inhibitors, including anastrozole, 
have proven efficacy for adjuvant therapy in postmenopausal women with breast cancer 
(Nabholtz, 2008; Rinaldi, 2013).  
New types of treatment are being tested in clinical trials in anticipation of discovering 
new methods and therapies that may ultimately lead to a cure for the disease.  Although breast 
cancer treatments are extending the lives of thousands, the treatments are often accompanied 
with an array of side effects that may negatively impact daily functioning and quality of life 
(Pullens et al., 2010).  Side effects vary based on the treatment type and may range from fatigue 
and nausea to pain, lymphedema, and osteoporosis (Hartmann, 2012).  As it has been well 
recognized that unfavorable effects are often experienced as a derivative of treatments such as 
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chemotherapy, women’s lives may be significantly altered as even routine activities of daily 
living become particularly difficult due to the decrease in function.  Functionality is 
demonstrated through physical, cognitive, and psychological abilities.  Among the more 
commonly reported side effects are fatigue, pain, and emotional distress (Bennett, Goldstein, 
Lloyd, Davenport, Hickie, 2004; Nabholtz, 2008; Tchen et. al., 2003; Pullens et al., 2010).  As 
these symptoms often co-exist, they manifest differently for each individual and may compound 
or increase the impact of symptoms on the individual and their ability to function in daily 
activities.  Bennett et al. (2004) encourage treatment providers to pay close attention to the 
patient’s experience of fatigue and routinely assess the potential of psychological distress, such 
as depression and anxiety, that may be accompanying or associated with current problematic 
symptoms. 
A decline in physical ability is most easily identifiable, whereas cognitive and 
psychological deteriorations are more difficult to clearly and objectively measure.  Under the 
cognitive domain, executive functions, include a variety of higher level thought processes such 
as concentration, monitoring, regulating, initiation, planning, etc., and allow an individual to 
independently function.  Executive functions are imperative for an individual to productively 
operate at home, work/school, and in society.  Therefore, if cognitive function is inhibited as a 
result of treatment, problems in those settings, including work, will likely arise. 
1.2.1. Effects of AIs/Anastrozole 
Adverse effects of anastrozole treatment are reported to have included fatigue, infection, 
fractures, osteopenia, osteoporosis, nausea, hot flashes, vomiting, and cognitive impairments 
(Nabholtz, 2008; Tchen et. al., 2003; Pullens, et al., 2010).  Cognitive dysfunction after treatment 
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has also been subjectively reported by women with breast cancer.  Pullens et al. (2010) 
concluded that subjective reports of cognitive dysfunction, in women with breast cancer, may be 
more indicative of emotional distress than objective measures, due to the relationship between 
subjective cognitive dysfunction and anxiety and depression.  The women’s subjective reports 
are reflections of their satisfaction of their cognitive functioning and may be directly related to 
effects of treatment. 
In a cross sectional study, Nattinger et al. (2013) compared cognitive function in a cohort 
of breast cancer survivors who had been exposed to AI agents to a control cohort of breast cancer 
survivors without AI exposure.  Age and educational levels of the participants were comparable. 
The participants’ cognitive function was measured by neuropsychological measures and task-
activated fMRI.  Due to the small sample size of 11 participants in each group, effect sizes were 
examined as an indicator of performance.  A trend emerged for the AI group (effect size of 0.3 or 
greater), showing poorer performance on all 12 tests of the neuropsychological assessments 
administered, suggesting an overall trend of worse cognitive function in the participants exposed 
to AI.  Additionally, during fMRI testing while completing a working memory task, the control 
group (no-AI) produced expected patterns of increased regional oxygenation as demands of the 
task increased, whereas the AI group failed to produce these results.  This study indicates the 
possibility of adverse effects of AI exposure on cognition. 
In another study with cross sectional design, Bender et al. (2007) examined memory 
impairments as a result of receiving tamoxifen compared to anastrozole.  Thirty-one women, 
ages ranging from 21 to 65, who received tamoxifen (n=16) or anastrozole (n=15) treatment for a 
minimum of 3 months, were incorporated in the study. Age, therapy duration, years of education, 
depression, anxiety, and fatigue were controlled for upon analysis.  A battery of validated and 
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reliable measures was used to assess cognitive function.  The results showed that women who 
received anastrozole had poorer verbal and visual learning and memory than women who 
received tamoxifen.  Bender et al. (2007) indicated in conclusion, cognitive impairments are 
capable of affecting overall quality of life, including occupational achievement. 
1.3 WORK PROBLEMS ASSOCIATED WITH BREAST CANCER AND 
TREATMENTS 
The literature suggests that adjuvant therapy, specifically anastrozole, may have negative affects 
on cognitive functioning (Bender et al., 2007; Nattinger et al., 2013).  Cognitive impairments 
contribute to the likelihood of increased work problems.  Therefore, in theory, anastrozole 
treatment may increase the likelihood of work problems. 
Aside from earning a livelihood, work is a central component of most individuals’ lives.  
Providing social and psychological benefits, work contributes to the overall wellbeing and 
identity of an individual (Szymanski & Parker, 2010).  Work after cancer is highly desirable for 
individuals on a person, social, and economic level, ultimately contributing to quality of life, 
dignity, self-esteem, and purpose (Steiner, Cavender, Main, & Bradley, 2004).  
Common concerns and experiences among women treated for breast cancer, in various 
positions and types of occupations, include job loss, demotion, unwanted changes in tasks, 
problems with the employer and co-workers, personal changes in attitudes to work and 
diminished physical capacity (Brisson et al., 1999).  It is important to assess the deteriorations in 
cognitive function, as well as physical and emotional function, resulting from breast cancer 
therapies and the subsequent impact on work ability.  Exploring these issues will promote better 
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understanding of work problems related to breast cancer, to facilitate better communication of 
functional limitations between employees, supervisors and coworkers and adjustment to potential 
work disability.   
In 2004, Steiner et al. (2004) published a commentary recognizing gaps in the existing 
literature concerning the work impact of cancer and its treatments. The commentary concluded 
that most of the research on return to work and work roles after cancer contained methodological 
errors, which limited the available literature.  Steiner added that while the reviewed literature 
recognized return to work rates, it failed to address contextual factors and economic impacts.  
The current study findings may add insight to the ICF core sets for breast cancer specifically 
related to the workplace.   It may also direct treatment decision making for breast cancer patients 
who are particularly concerned about their ability to perform at work post treatment. 
1.4 SIGNIFICANCE OF STUDY 
As higher percentages of breast cancer survivors are returning to work and/or continuing to 
maintain employment after and even during treatment, it is necessary to examine the effects of 
breast cancer treatments as it relates to the individual’s ability to function at work.  Furthermore, 
identifying work problems and analyzing the impact in specific work contexts will supplement 
the current literature.  
Ethical considerations need to be upheld when making the ultimate decision on breast 
cancer treatment, based on healthcare provider recommendations and patient concerns.  Do the 
potential benefits from particular treatments outweigh the potential harm caused by the selected 
treatment?  Women with breast cancer who plan to return to or continue to work, will need to 
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evaluate the potential outcomes of treatment and how that will impact their functioning in the 
workplace, in addition to other areas of life.  Necessary vocational rehabilitative supports, 
services, and funding for services should also be a point of priority in discussion when 
considering post-treatment plans for maintaining or returning to work. 
1.5 SPECIFIC AIMS 
The purpose of this study was to examine work problems through a critical analysis of self-
reported data of women receiving breast cancer treatment, specifically anastrozole.  Additionally, 
the study aimed to identify potential work performance limitations after receiving anastrozole 
treatment as compared with controls (women that were postmenopausal, who did not have breast 
cancer nor had undergone any systemic therapy or treatment) and compared within-subjects 
overtime.  Work performance limitations and functions were analyzed under three domains 
(affective, physiological, and cognitive), as they impact functioning associated with work.     
1.5.1 Hypotheses 
After a critical review of the current available literature, the following hypotheses were 
established: 
Hypothesis 1: Postmenopausal women with breast cancer self-report (a) higher numbers 
and (b) greater severity of work problems as compared with the control group, at 
baseline, prior to treatment. 
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Hypothesis 2: Postmenopausal women with breast cancer receiving anastrozole treatment 
self-report (a) higher numbers and (b) greater severity of work problems as compared to 
the control group, at pre-treatment, 6 months, and 18 months post initial treatment. 
Hypothesis 3: Postmenopausal women with breast cancer will self-report (a) higher 
numbers and (b) greater severity of work problems over time. 
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2.0  METHODS 
2.1 STUDY DESIGN 
This study was a retrospective analysis of data that was collected longitudinally to evaluate the 
impact on work performance through self-reported data of postmenopausal women receiving 
anastrozole treatment for breast cancer.  A control group was incorporated in the study that 
included women that were postmenopausal, who did not have breast cancer nor had undergone 
any systemic therapy or treatment.  The longitudinal data was originally collected for the 
Anastrozole Use In Menopausal Women (AIM) study (R01 CA 107408), directed by primary 
investigator, Dr. Catherine Bender.  The National Institutes of Health (NIH) provided funding for 
the AIM study.  Approval for the present study was obtained from the University of Pittsburgh 
Institutional Review Board (IRB) prior to receiving access to data (PRO14010224).  Records 
gathered from the original study and used in this secondary analysis were data collected by self-
report from the participants during the AIM study from October 2005 through 18-months post 
treatment.  A comparison of the treatment and control groups and a critical analysis of the data 
was conducted at baseline, 6 months post treatment, and 18 months post treatment to examine 
the magnitude of change in work problems over time.  The specific time points were selected for 
this analysis due to greater amounts of subjective data were reported and available at those time 
points.  
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 2.2 PARTICIPANTS 
Participants consisted of a sample of postmenopausal women who participated in the AIM study 
from October 2005 through 18-months post treatment.  The AIM study recruited the participants 
from the Comprehensive Breast Care Program of the University of Pittsburgh Cancer Institute 
and the University of Pittsburgh Medical Center Cancer Centers.  The women were diagnosed 
with stage I, II, and IIIa breast cancer and were eligible to receive hormonal therapy with or 
without chemotherapy.  Random digit dialing was used to recruit controls that were healthy 
menopausal women.  The controls were matched with treatment participants on age and years of 
education (Bender et al., 2013). 
A member of the team from the original study de-identified the data, prior to providing it 
to the investigator, assigned linkage codes, but did not provide the investigator with access to the 
linkage codes.  The member of the team from the original study was not associated with this 
research study and only had access to the records for this study for the purpose of de-identifying 
the data.   
2.2.1 Eligibility 
Participants’ eligibility criteria for this study were adopted from the original AIM study.  
According to the previous study (R01 CA 107408), the inclusion criteria for all participants were 
as follows: (a) female; (b) postmenopausal, defined as: 1) amenorrhea persisting for an entire 
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year, 2) oophorectomy, or 3) hysterectomy and age greater than 51 years (average age of 
menopause in the U.S.); (c) maximum age of 75 years; (d) able to speak and read English, 
(neuropsychological tests are normed on English speakers); (e) have completed a minimum of 8 
years of education, due to the 8th-grade reading levels required to complete some 
neuropsychological tests.  Additional inclusion criteria for the anastrozole treatment intervention 
group included: (a) diagnosed with stage I, II, and IIIa breast cancer based on the Tumor, Node, 
Metastasis Classification System and confirmed by each subject's medical oncologist; (b) eligible 
to receive either chemotherapy + anastrozole, chemotherapy alone or anastrozole alone.  
Additional inclusion criteria for the control group included: (a) matched on age, race and level of 
education with experimental participants; (b) no current or history of any cancer, due to the 
potential confounding effects of preexisting disease and treatment; (c) not currently taking any 
form of hormone replacement therapy (HRT). 
Exclusion criteria for all participants included the following: (a) self-report of 
hospitalization for psychiatric illness within the last 2 years, due to the increased risk for 
cognitive impairment in patients with a history of psychiatric illness; (b) have a prior diagnosis 
of neurologic illness such as stroke, multiple sclerosis, dementia syndrome, or Parkinson’s 
disease or of HIV-related dementia or chronic fatigue syndrome, due to the potential 
confounding effect of these illnesses on cognitive function.  Additional exclusion criteria for the 
anastrozole treatment intervention group included: (a) clinical evidence of distant metastases 
including the central nervous system, due to the potential confounding effect of metastatic 
disease on cognitive function; or (b) prior diagnosis of cancer, due to the potential confounding 
effects of preexisting disease and therapy.  The table below is included to clearly show the 
eligibility inclusion and exclusion criteria for participants in study. 
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Table 1. Eligibility criteria 
Participants Inclusion Criteria Exclusion Criteria 
All 
participants 
(a) female 
(b) postmenopausal, defined as: 
1) amenorrhea persisting for an
entire year, 
2) oophorectomy, or
3) hysterectomy and age greater
than 51 years  
(c) maximum age of 75 years 
(d) able to speak and read English  
(e) have completed a minimum of 8 
years of education 
(a) self-report of hospitalization for 
psychiatric illness within the last 2 years 
(b) have a prior diagnosis of neurologic 
illness such as stroke, multiple sclerosis, 
dementia syndrome, or Parkinson’s 
disease or of HIV-related dementia or 
chronic fatigue syndrome 
Anastrozole 
only 
(a) diagnosed with stage I, II or IIIa 
breast cancer based on the Tumor, 
Node, Metastasis Classification 
System and confirmed by each 
subject's medical oncologist 
(b) eligible to receive either 
chemotherapy + anastrozole, 
chemotherapy alone or anastrozole 
alone. 
(a) clinical evidence of distant 
metastases including the central nervous 
system  
(b) prior diagnosis of cancer  
Controls 
only 
(a) matched on age, race and level of 
education with experimental 
participants 
(b) no current or history of any cancer 
(c) not currently taking any form of 
hormone replacement therapy (HRT). 
2.3 OUTCOME INSTRUMENTATION 
All data were de-identified prior to the investigator’s access.  Data were analyzed at baseline 
(prior to treatment), 6 months post initial treatment, and 18 months post initial treatment.  The 
self-reported questionnaire data, containing the variables being examined, included: (a) Baseline 
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Demographic/Health Questionnaire, (b) Follow-up Health Questionnaire, (c) Patient Assessment 
of Own Functioning Inventory (PAOFI), (d) Medical Outcomes Study Short Form 36 Health 
Survey (SF-36), (e) Beck’s Depression Inventory-II (BDI-II), (f) Fatigue/Inertia Subscale of the 
Profile of Mood States (POMS), and (g) Brief Pain Inventory (BPI).  The PAOFI and SF-36 –
work items were primarily used to measure work problems, the Follow-up Health Questionnaire 
was incorporated to assess open-ended qualitative information, which may include work 
problems.  The BDI-II, POMS, and BPI were also incorporated to explore potential covariates 
that could impact cognitive, affective, and physiological functioning and the perception of work 
limitations.  
Table 2. Description of study objectives and corresponding data needed for analysis 
Data measure(s) Objective(s)      Scoring 
Baseline Demographic/Health 
Questionnaire 
To establish baseline 
demographics of research 
participants to compare with 
data collected at succeeding 
time points. 
26-question survey was 
designed to capture 
information pertaining to 
personal demographics, 
physical health, breast cancer, 
and hormonal 
status/reproductive history.  
Follow-up Health 
Questionnaire 
 
To identify self-reported 
changes occurred at specific 
time points (6 months post 
initial treatment and 18 
months post initial treatment). 
6 didactic questions, 
additionally requesting open-
ended detail when necessary.  
Questions asked about the 
occurrence of significant 
changes since the individual’s 
previous meeting. 
Patient Assessment of Own 
Functioning Inventory 
(PAOFI) 
 
To analyze participants’ self-
reported assessment of own 
functioning. 
6-point scale ranging from 
almost never to almost 
always. 
Higher scores representing 
worse impairment and lower 
scores denoting less to no 
impairment. 
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Table 2. (continued) 
Data measure(s) Objective(s)      Scoring 
Medical Outcomes Study 
Short Form 36 Health Survey 
(SF-36)–work items 
 
To identify participants self-
reported problems at work as a 
result of physical health and 
emotional health. 
36-item self-report measure of 
functional ability.  Of the SF-
36 - work items that were 
analyzed, scores ranging from 
7-35 were possible.  These 
scores assessed physical and 
psychological functioning.   
Higher scores indicated better 
functioning. 
Beck’s Depression Inventory-
II 
 
To identify factors associated 
with affective and cognitive 
limitations as related to work 
problems. 
21-question self-report 
inventory measuring the 
degree and severity of 
depression. Scores range from 
0-63 and the higher the score, 
the more severe the 
depression.  
Fatigue/Inertia Subscale of the 
Profile of Mood States 
(POMS) 
 
To identify factors associated 
with physiological and 
affective issues as related to 
work problems. 
7-item self-report survey, a 
portion of the full Profile of 
Mood States (POMS). A 5-
point Likert scale format is 
used to indicate the degree to 
which the adjective describes 
the subject’s condition over 
the last week.   
High scores indicated 
increased fatigue. 
Brief Pain Inventory (BPI) 
 
To identify factors associated 
with physiological issues as 
related to work problems. 
7-item medical questionnaire 
to assess the severity of pain 
and the impact of pain on 
daily functions.  Pain is 
scored from 0-10 for each 
items.   
The higher the total or 
average, the more severe the 
pain. 
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2.3.1 Baseline Demographic/Health Questionnaire and Follow-up Health Questionnaire 
The Baseline Demographic/Health Questionnaire was a 26-question survey was designed to 
capture information pertaining to personal demographics (i.e. age, education, occupation, 
language, etc.), physical health, breast cancer, and hormonal status/reproductive history.  The 
Follow-up Health Questionnaire included 6 “yes or no” questions, additionally requesting open-
ended detail when necessary.  The questions asked about the occurrence of significant changes 
since the individual’s previous meeting.  The Follow-up Questionnaire was completed during the 
6-month post treatment and 18-month post treatment intervals.  Both the Demographic/Health 
Questionnaire and the Follow-up Questionnaire consisted of subjective information provided by 
the study participants.  Psychometric properties of these questionnaires have not been evaluated 
due to the creation of the Follow-up Health Questionnaire as an alternative method of gathering 
information at 6-months and 18-months post treatment.  While administering the Baseline 
Demographic/Health Questionnaire repeatedly would provide test-retest reliability, the Follow-
up Health Questionnaire consisted of items that targeted post treatment results specifically.  
2.3.2 Patient Assessment of Own Functioning Inventory (PAOFI) 
The Patient Assessment of Own Functioning Inventory (PAOFI) was a 47-item survey that 
incorporated both physiological and cognitive function into 5 domains.  The PAOFI inquired 
about the participant’s frequency of everyday difficulties including memory, higher-level 
cognition and intellectual functions, use of hands, sensory-perceptual functions, and language 
and communication.  With thirty-three questions related to difficulties with functioning, the 
inventory used a 6-point scale ranging from almost never to almost always; higher scores (198 
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highest possible) on the PAOFI indicated no perceived impairment and lower scores (33 lowest 
possible score) indicated highest degree of perceived impairment (Chelune, Heaton, & Lehman, 
1986).  For the present study the scoring scale was reversed to reflect higher scores representing 
worse impairment and lower scores denoting less to no impairment. 
Reliability and validity studies have been limited and not yet established in diverse 
populations, including breast cancer (Bell, Terhorst, & Bender, 2013).  To assess the 
psychometric properties of the PAOFI in the population of interest, Bell et al. (2013) conducted 
secondary analysis of reliability and validity of the PAOFI in a sample of postmenopausal 
women with early-stage breast cancer prior to adjuvant therapy.  By correlating PAOFI scores 
with Profile of Moods States (POMS) and Medical Outcome Study Short Form-36 (SF-36) 
scores, construct validity was examined.  Exploratory factor analysis was performed to further 
explore the factor structure of the PAOFI.  Baseline data from a sample of 259 participants from 
the Anastrozole Use in Menopausal Women (AIM) Study (R01 CA107408) was used in this 
secondary analysis.  The baseline data was collected after participants (postmenopausal women 
who had undergone surgery for early-stage breast cancer) completed primary breast surgery but 
prior to the start of adjuvant therapy.  The five-factor structure generated the following 
categories: Higher Level Cognitive & Intellectual Function, Language & Communication, 
Memory I, Sensorimotor, and Memory 2.  Using Cronbach’s alpha, reliabilities for the PAOFI 
subscale were calculated resulting in the following Cronbach’s alpha scores: Memory I = .818, 
Memory 2 = .744, Language & Communication = .792, Sensorimotor = .572, and 
Cognitive/Intellectual Functions = .883.  All categories were considered to have adequate 
internal consistencies except for Sensorimotor (Bell et al., 2013).   Using the exploratory factor 
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analysis categories, correlations of PAOFI subscales with POMS Fatigue and SF-36 subscales 
supported the construct validity of the use of the tool in the particular population. 
2.3.3 Medical Outcomes Study Short Form 36 Health Survey (SF-36) 
The Medical Outcomes Study Short Form 36 Health Survey (SF-36) was a 36-item self-report 
measure of functional ability to monitor and assess care outcomes in adult patients (Ware, 
Snow, Kosinski, & Gandek, 1993; Ware & Sherbourne, 1992).  The survey assesses eight health 
concepts, including: limitations in physical activities because of health problems, limitations in 
social activities because of physical or emotional problems, limitations in usual role activities 
because of physical health problems, bodily pain, general mental health (psychological distress 
and well-being), limitations in usual role activities because of emotional problems, vitality 
(energy and fatigue), and general health perceptions.  Standardized scores, ranging from 0-100, 
were used to assess physical and psychological functioning.  Higher scores indicated 
better functioning (Bell et al., 2013).  From the SF-36, only items numbered 4 and 5, which 
covered the ‘limitations in usual role’, were incorporated in the study as those items 
specifically targeted work limitations due to physical health problems and psychological health 
problems.  The work items were the only items of the SF-36 that were used for analysis.  
McHorney, Ware, Rachel Lu, and Sherbourne (1994) studied the psychometric properties 
of the SF-36 across diverse populations with 3,445 patients with 24 subgroups to reflect 
diversity.  The study supported the measure’s item-internal consistency and item-discriminant 
validity across all groups.    Reliability coefficients varied some across subgroups and ranged 
from 0.65 to 0.94 across scales.  These findings support the use of the SF-36 tool in populations 
of various socioeconomic characteristics, health conditions or diseases, and disease severity. 
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2.3.4 Beck’s Depression Inventory – II 
Incorporated as a study measure of affective functioning, Beck’s Depression Inventory-II was a 
21-question self-report inventory measuring the degree and severity of depression (Beck, Steer, 
Brown, 1996).  The highest possible score on a BDI-II is sixty-three and the lowest possible 
score is zero.  The higher the score, the more severe the depression.  The BDI-II is a widely 
accepted and extensively utilized assessment for evaluating depression in patients with 
psychiatric diagnoses and in non-psychiatric populations.  The original BDI has demonstrated 
efficacy in adequately maintaining internal consistency, test-retest reliability, and construct 
validity (Dozois, Dobson, & Ahnberg, 1998).  The BDI-II was developed to be more compatible 
with the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria once the DSM-IV 
was developed.  In a study sampling 1,022 college students the BDI–II has been found to 
demonstrate high levels of internal consistency with an alpha coefficient of 0.89 for the BDI and 
0.91 for the BDI-II.  The correlation of validity scores between the two instruments  (0.93) 
supported the convergent validity of the BDI-II.  In the same study, factor analysis was also run 
which identified two main factors, Cognitive-Affective and Somatic-Vegetative, summarized the 
data (Dozois, Dobson, & Ahnberg, 1998).  The source suggests that the BDI-II is more 
congruent with the DSM-IV and more robust in its factor structure than the BDI. 
2.3.5 Fatigue/Inertia Subscale of the Profile of Mood States (POMS) 
The Fatigue/Inertia Subscale was a 7-item self-report survey, a portion of the full Profile of 
Mood States (POMS), and utilized in the study as a physiological measure of (McNair, Lorr, & 
Droppleman, 1992).  The complete POMS comprises of 65 adjectives under 6 subscales: tension-
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anxiety, depression, anger-hostility, vigor-activity, fatigue, and confusion-bewilderment.  The 
Fatigue/Inertia Subscale measures the impact of fatigue among the overall context and purpose 
of the tool to ultimately assess psychological distress.  A 5-point Likert scale format is used to 
indicate the degree to which the adjective describes the subject’s condition over the last week.  
High scores indicated increased fatigue.  The tool is used across a variety of clinical and research 
settings and has achieved acceptance as a measure of psychological distress in healthy, 
physically ill, and psychiatric populations (Curran, Andrykowski, & Studts, 1995).  Internal 
consistency estimates for the Subscale Scores for the Profile of Mood States (POMS) and the 
POMS-Short Form (POMS-SF) were assessed in a population of breast cancer patients, and other 
populations.  The Cronback’s alpha for the fatigue scales resulted in 0.90 for the POMS and 0.89 
for the POMS-SF (Curran et al., 1995).  These results justify the usage of the subscales as 
opposed to the entire original POMS survey in clinical and research settings.  Additionally, the 
POMS has concurrent validity with the BDI. 
2.3.6 Brief Pain Inventory 
Operating as a study measure of physiological function, the Brief Pain Inventory (BPI) was a 17-
item medical questionnaire to assess the severity of pain and the impact of pain on daily 
functions (Cleeland, 1991).  Pain is scored from 0-10 for each item.  The higher the total or 
average score, the more severe the pain.  Both total scores and average scores are used clinically.  
Recognized as a standard tool for assessing self-reported pain, the instrument is widely used in 
clinical settings and numerous studies for individuals with chronic diseases or conditions, 
including cancer.  Designed with a two-factor structure, the BPI aims to capture severity and 
interference of pain.  Furthermore, it also intends to capture the activity and affective 
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components of interference.  Among the original studies of the tool, the BPI was tested across 
four language versions.  Factor analysis was applied to the matrix of intercorrelations for each 
item.  Results revealed that the individuals experiencing cancer and pain who completed the BPI 
responded to the items in a similar fashion, although living in different countries and speaking 
various languages (Cleeland, 2009).   
A larger factor analysis study completed in the US involving 1261 subjects concluded 
good internal consistency, with Cronbach alphas ranging from 0.80 to 0.87 for the severity of 
pain items and from 0.89 to 0.92 for the interference items (Cleeland, 2009).  The BPI has 
proven a reliable tool supported by the assessment of its high test-retest reliability and alternate-
form reliability examined in a study completed in 1999 based on 100 patients with cancer taking 
both the English and Hindi forms of the BPI on different days.  The alternate-form reliability of 
the interference subscale was 0.88 and the reliability of the severity subscales was 0.95.  These 
high rates of reliability are demonstrated when pain is stable or when pain changes in a 
predictable way (Cleeland, 2009). 
2.4 DATA COLLECTION 
Following approval for the study (PRO14010224), granted by the University of Pittsburgh 
Institutional Review Board (IRB), data were obtained from its source through an honest broker.  
Records gathered from the original study and used in this secondary analysis were teleform data 
that was collected by self-report from the participants and all data were de-identified prior to the 
investigator’s viewing.  Specific variables of selected measures, namely the Baseline 
Demographic/Health Questionnaire, Follow-up Health Questionnaire, and SF-36, were requested 
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based on utility and relevance of the variables to the aims of the study.  Other measures required 
that all items be requested to assess the value of the individual items and of the test as a whole.  
The following table lists the data measures and the specific variables requested from the 
respective instrument. 
 
Table 3. Data measures and key variables requested for analysis. 
Data measure(s) requested  Data variable(s) 
 
Baseline Demographic/Health 
Questionnaire 
Item #s (including additional 
corresponding details for each 
item): 
Section A: 2, 3, 4, 5, 6, 7, 8, 9, 
10 
Section B: 11 
Section C: 12, 13, 14, 15, 16 
Section D: 20, 21 
 
Follow-up Health 
Questionnaire 
All items (including additional 
corresponding details for each 
item) 
 
Patient Assessment of Own 
Functioning Inventory 
(PAOFI) 
 
All items 
Medical Outcomes Study Short 
Form 36 Health Survey (SF-
36) 
 
Item #s: 
4 and 5 only (work items) 
Beck’s Depression Inventory-II 
 
All items 
Fatigue/Inertia Subscale of the 
Profile of Mood States (POMS) 
 
All items 
Brief Pain Inventory (BPI) All items 
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2.4.1 Data condensing of Baseline Demographic/Health Questionnaire 
Due to small sample sizes, multiple variables from the original data were collapsed into 
transformed data to simplify the information for the utility of analysis.  Below in Table 4 is a 
reference identifying the variable, original measures, and transformed measures.  A few 
measures were recorded as continuous data but were transformed to intervals for simpler 
understanding.  Any original measures that did not appear in the transformed column were 
because there were no data for that specific measure.  Handedness, for instance, had original 
measures of “Yes”, “No”, or “Both”, but none of the participants reported to be “Both”, therefore 
the transformed measure did not include the “Both” measure.  Other measures, which were 
similar in nature, were combined to form measures such as marital statuses like “Currently 
married or living with partner” and  “Separated or divorced”, instead of standing independent.  
For the purposes of this study these details were used as a general understanding of the 
demographics of the participants and did not need to be examined closely unless outliers or 
skewness presented. 
 
Table 4. Original and transformed demographic data. 
 
Variable 
 
Original Measure 
 
Transformed Measure 
 
Age in years Continuous 40-60 y OR 
61-80 y 
Years of 
Education 
Continuous 6-13 y OR 
14-17 y OR 
18-29 y 
English as native 
language 
Yes OR 
No 
Yes OR 
No 
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Table 4. (Continued) 
Race White OR 
Black/African American OR 
American Indian OR 
Alaska Native OR 
Native Hawaiian or Pacific Islander OR 
Asian OR 
Unknown OR 
Other 
White OR 
African American 
Handedness Right OR 
Left OR 
Both 
Right OR 
Left 
Marital Status Never married OR 
Currently married OR 
Living with partner/significant other OR 
Widow OR 
Separated OR 
Divorced 
Never married or 
widowed OR 
Currently married or 
living with partner OR 
Separated or divorced 
Number of 
children 
Continuous No children OR 
1-4 OR 
5-8 
Occupation Higher execs, major professionals, owners of 
large businesses OR 
Managers of medium sized businesses, nurses, 
opticians, pharmacists, social workers, 
teachers OR  
Administrative personnel, managers, minor 
professionals, owners/proprietors of small 
businesses:  bakery... OR 
Clerical and sales, technicians, bank teller, 
bookkeeper, clerk, draftsperson, timekeeper, 
secretary... OR 
Skilled manual – usually having had training 
(baker, barber, brake-person, chef, electrician, 
fireperson...OR  
Semi-skilled (hospital aide, painter, bartender, 
bus driver, cutter, cook, drill press, garage 
guard... OR 
Unskilled (attendant, janitor, construction 
helper, unspecified labor, porter, including 
unemployed.) OR 
Homemaker OR  
Student, disabled, no occupation, retired. 
Major professionals OR 
Minor professionals OR 
Clerical, sales, 
technicians OR 
Skilled or semi-skilled 
OR 
Unskilled, homemaker 
OR 
Student, disabled, retired, 
no occupation 
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Table 4. (Continued) 
Gone through 
natural menopause 
Yes OR 
No OR 
Does not know 
Yes OR 
No or does not know 
Date of BC 
diagnosis 
Continuous 1/1/2005 – 12/31/2007 
OR 
1/1/2008 – 12/31/2010 
OR 
1/1/2011 – 12/31/2013 
Date of first 
surgery 
Continuous 1/1/2005 – 12/31/2007 
OR 
1/1/2008 – 12/31/2010 
OR 
1/1/2011 – 12/31/2013 
Type of surgery 
(first surgery) 
Modified Radical Mastectomy OR 
Total or Simple OR 
Breast-conserving surgeries (BCS) OR 
BCS & Sentinel Node Biopsy OR 
BCS & Axillary Node Dissection OR 
Other 
Modified Radical 
Mastectomy OR 
Total or Simple OR 
Breast-conserving 
surgeries (BCS) OR 
BCS & Sentinel Node 
Biopsy OR 
BCS & Axillary Node 
Dissection OR 
Other 
Date of second 
surgery 
Continuous 1/1/2005 – 12/31/2007 
OR 
1/1/2008 – 12/31/2010 
OR 
1/1/2011 – 12/31/2013 
Type of surgery 
(second surgery) 
Modified Radical Mastectomy OR 
Total or Simple OR 
Breast-conserving surgeries (BCS) OR 
BCS & Sentinel Node Biopsy OR 
BCS & Axillary Node Dissection OR 
Revision OR 
Other 
Modified Radical 
Mastectomy OR 
Total or Simple OR 
Breast-conserving 
surgeries (BCS) OR 
BCS & Sentinel Node 
Biopsy OR 
BCS & Axillary Node 
Dissection OR 
Revision OR 
Other 
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Table 4. (Continued) 
Stage of breast 
cancer 
LCIS OR 
DCIS OR 
Stage 1 OR 
Stage 2a OR 
Stage 2b OR 
Stage 3a 
Stage 1 OR 
Stage 2a OR 
Stage 2b OR 
Stage 3a 
2.4.2 Selected variables of the Follow-up Health Questionnaire  
Originally, all of the items of the Follow-up Health Questionnaire were requested for analysis 
and selected to undergo evaluation.  Each question required a “yes” or “no” response and if the 
participant responded “yes”, further open-ended description was requested.  Of the six items, the 
results from question 5, “Have you had any other significant changes in life since our last 
meeting,” were found to be most applicable for this study and therefore were the only data 
incorporated in the results for hypothesis #3.  As the other questionnaire items mostly pertained 
to health related concerns, question 5 remained open for potential reports of work related issues.  
Only the anastrozole group’s results were assessed, in line with the aims of the hypothesis. 
2.4.3 Selected variables of the Medical Outcomes Study Short Form 36 Health Survey 
(SF-36)  
Based on the aims of the study, only items #4 and #5 of the SF-36 were used for analysis because 
the variables directly inquired about the impact of either physical or emotional health on ability 
to perform at work or other regular activities.  For both questions and sub-questions, a Likert 
scale was used to score the responses.  The following are examples of questions #4 and #5. 
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Question 4:  During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of your 
physical health? 
a) Cut down on the amount of time you spent on work or other activities 
b) Accomplished less than you would like 
c) Were limited in the kind of work or other activities 
d) Had difficulty performing the work or other activities (for example, it took 
extra effort) 
Question 5:  During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
a) Cut down on the amount of time you spend on work or other activities 
b) Accomplished less than you would like 
c) Did work or other activities less carefully than usual 
2.5 STATISTICAL ANALYSIS 
Data were analyzed using IBM SPSS Statistics Version 22.0.   IBM SPSS statistics was a 
software program used for statistical analysis (IBM Inc., 2013).  Distributions were analyzed 
using frequencies, means, and standard deviations.  Alpha levels set at 0.05 a priori.  Descriptive 
statistics were run.  Baseline differences were analyzed using χ2 (categorical data) and t-tests for 
continuous data. 
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Hypothesis 1: Postmenopausal women with breast cancer self-report (a) higher 
numbers and (b) greater severity of work problems as compared with the control group, at 
baseline, prior to treatment. 
Hypothesis 1 was tested at baseline with independent sample t-tests to assess if 
differences existed between the group with anastrozole treatment and the control group.  Prior 
analysis was also conducted to identify if missing or skewed data were present in the samples at 
baseline and to adjust for if necessary.  Descriptive statistics were used to assess missing and 
skewed data using frequencies and percentages for all categorical variables, means, and standard 
deviations for all continuous variables as applicable. 
Hypothesis 2: Postmenopausal women with breast cancer receiving anastrozole 
treatment self-report (a) higher numbers and (b) greater severity of work problems as 
compared to the control group, at pre-treatment, 6 months, and 18 months post initial 
treatment. 
Hypothesis 2 was assessed using repeated measures to control for experimental 
variability and to examine changes in number and severity of work problems.  Participants will 
act as their own controls (within-subject design).  A 2 x 3 mixed analysis of variance (ANOVA) 
was conducted to determine if there were significant differences in self-reported work problems 
or limitations on work performance, between the group receiving anastrozole and the control 
group, at baseline, 6 months, and 18 months post initial treatment.  This analysis was used to 
identify if there were differences in work problems between the two groups, overtime.  Figure 1 
is provided as a visual diagram to assist in depicting the method of analysis. 
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 Pre-treatment 6 months 18 months 
Anastrozole Group    
Control Group    
Figure 1. 2x3 Mixed Model ANOVA conceptual diagram 
 
Hypothesis 3: Postmenopausal women with breast cancer receiving anastrozole will 
self-report (a) higher numbers and (b) greater severity of work problems over time. 
Hypothesis 3 was assessed using repeated measures to examine changes in frequency and 
severity of work problems.  Only results from the anastrozole group were assessed to target the 
aim of Hypothesis #3.  Due to the limited open-ended response rate of work problems, 
qualitative analysis was conducted to identify reported changes in work, including both positive 
and negative changes.  
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3.0  RESULTS 
3.1 DESCRIPTIVE STATISTICS 
Two hundred and seventy-one total individuals participated in the study, all of who were 
females.  The participants were divided into two groups. The first group, referred to as the 
anastrozole group, included women with breast cancer who received anastrozole treatment and 
the second group, controls, consisted of women of like demographic makeup but did not have 
breast cancer nor the anastrozole treatment.  
Based on the information collected from the participants’ de-identified baseline 
demographics, the mean age of the participants in the anastrozole group was 59.9 years (SD= 
5.6; range= 44.3 – 71.5) and the mean age of the participants in the control group was 59.5 (SD= 
5.8; range= 42.5 – 74.9).  To examine distribution and concentration of age, age was also 
separated by age range for each group (Table 5).  For both groups, there were more participants 
in the 40-60 age range than the 61-80 range.  The years of education of the samples were 
likewise divided into ranges to further examine the distribution of years of education.  The 
categories of years of education were 6-13 years, 14-17 years, and 18-29 years.  The racial 
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makeup of the sample was predominantly white (anastrozole: 93.8%, n= 126; control: 97.9%, n= 
140) and the only other ethnicity reported for each group was African American (anastrozole: 
6.3%, n= 8; control: 8.4%, n= 12).   
Information on participants’ occupational levels was examined at baseline.  The data 
were grouped into multiple categories with occupational labels but an explanation for how the 
categories were originally created was not available.  For purpose of statistical analysis, some 
categories were consolidated to create six total occupational categorical groupings: (1) major 
professionals, (2) minor professionals, (3) clerical, sales, technicians, (4) skilled or semi-skilled, 
(5) unskilled, homemaker, (6) student, disabled, retired, no occupation.  Major professionals 
(anastrozole: 21.9%, n= 28; control: 24.5%, n= 35) consisted of occupations such as: higher 
executives, major professionals, owners of large businesses, managers of medium sized 
businesses, nurses, opticians, pharmacists, social workers, teachers.  Minor professionals (10.2%, 
n= 13; control: 27.3%, n= 39) consisted of occupations such as: administrative personnel, 
managers, minor professionals, and owners/proprietors of small businesses.  The clerical, sales, 
technician category (anastrozole: 22.7%, n=29; control: 23.8%, n= 34) consisted of occupations 
such as:  clerical and sales, technicians, bank teller, bookkeeper, clerk, draftsperson, timekeeper, 
and secretary.  Skilled or semi-skilled occupations (anastrozole: 11.7%, n= 15; control: 7%, n= 
10) consisted of: usually having training (baker, barber, brake person, chef, electrician, 
fireperson) or semi-skilled jobs (hospital aide, painter, bartender, bus driver, cutter, cook, drill 
press, garage guard).  Unskilled, homemaker occupations category (anastrozole: 8.6%, n= 11; 
control: 6.3%, n= 9) consisted of: attendant, janitor, construction helper, unspecified labor, 
porter, including unemployed and homemaker.  Lastly, the sixth category consisted of students, 
individuals who were disabled, and individuals who had no occupation or were retired 
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(anastrozole: 25.0%, n=32; control: 11.2%, n= 16).  Information was additionally collected on 
participants’ demographic reports on native speaking language, handedness, marital status, 
number of children, and whether they had gone through menopause.  See table 5 for frequencies 
and percentages of each domain of demographic information at baseline.   
Between groups at baseline, there were no significant differences found in demographic 
information in all categories except for occupations.  The occupations between the anastrozole 
group and the control group were significantly different (p= .001).  Overall, there were higher 
percentages of women from the control group reporting employment as major professionals, 
minor professionals, and clerical/sales/technicians as there were from the anastrozole group.  
Additionally to be recognized, 25.0% of the anastrozole group, over double the 11.2% of the 
control group, reported to be in the category of “student, disabled, retired, or no occupation”.  
These results likely contributed greatly to the skewness of baseline demographic data for 
occupations. 
Separately, information was gathered on the women with breast cancer, at baseline, prior 
to having anastrozole treatment.  This information, displayed in table 6, included date of breast 
cancer diagnosis, date of first surgery and type of surgery, date of second surgery and type, and 
stage of breast cancer.  All 128 total women with breast cancer reported on this information.  
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Table 5.  Baseline demographics. 
Variable, mean (SD) 
or no. (%) 
Anastrozole 
n=128 
Control 
n=143 
Anastrozole group 
vs. Control group 
p Value 
 
Age in years 
  Mean (SD) 
  Minimum 
  Maximum 
 
59.9 (5.6) 
44.3 
71.5 
 
59.5 (5.8) 
42.5 
74.9 
0.688 
Age 
  40 – 60 y 
  61 – 80 y 
 
73 (57.0) 
55 (43.0) 
 
85 (59.4) 
58 (40.6) 
0.688 
Years of Education 
  6 – 13 y 
  14 – 17 y 
  18 – 29 y 
 
48 (37.5) 
49 (38.3) 
31 (24.2) 
 
47 (32.9) 
63 (44.1) 
33 (23.1) 
0.608 
English as native language 
  Yes 
  No 
 
126 (93.8) 
2 (1.6) 
 
140 (97.9) 
3 (2.1) 
0.744 
Race 
  White 
  African American 
 
120 (93.8) 
8 (6.3) 
 
131 (91.6) 
12 (8.4) 
 
0.501 
 
 
Handedness* 
  Right 
  Left 
 
117 (91.4) 
11 (8.6) 
 
120 (85.1) 
21 (14.9) 
0.111 
Marital Status 
  Never married or widowed 
  Currently married or living 
with partner 
  Separated or divorced 
 
22 (17.2) 
85 (66.4) 
 
21 (16.4) 
 
21 (14.7) 
84 (58.7) 
 
38 (26.6) 
0.128 
Number of children 
  No children 
  1 – 4 
  5 - 8 
 
27 (21.1) 
89 (69.5) 
12 (9.4) 
 
25 (17.5) 
103 (72.0) 
15 (10.5) 
0.740 
Occupation 
  Major professionals 
  Minor professionals 
  Clerical, sales, technicians 
  Skilled or semi-skilled 
  Unskilled, homemaker 
  Student, disabled, retired, no 
occupation 
 
28 (21.9) 
13 (10.2) 
29 (22.7) 
15 (11.7) 
11 (8.6) 
32 (25.0) 
 
35 (24.5) 
39 (27.3) 
34 (23.8) 
10 (7.0) 
9 (6.3) 
16 (11.2) 
0.001 
Gone through natural 
menopause 
  Yes 
  No or does not know 
 
 
104 (81.3) 
24 (18.8) 
 
 
122 (85.3) 
21 (14.7) 
0.369 
*Missing data: 2 
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Table 6.  Baseline demographics – Anastrozole only group 
Variable, no. (%) 
 
Anastrozole 
n=128 
 
Date of BC diagnosis 
  1/1/2005 – 12/31/2007 
  1/1/2008 – 12/31/2010 
  1/1/2011 – 12/31/2013 
 
47 (36.7) 
61 (47.7) 
20 (15.6) 
Date of first surgery* 
  1/1/2005 – 12/31/2007 
  1/1/2008 – 12/31/2010 
  1/1/2011 – 12/31/2013 
 
42 (32.8) 
63 (49.2) 
20 (15.6) 
Type of surgery (first surgery) 
  Modified Radical Mastectomy 
  Total or Simple 
  Breast-conserving surgeries (BCS) 
  BCS & Sentinel Node Biopsy 
  BCS & Axillary Node Dissection 
  Other 
 
10 (7.8) 
15 (11.7) 
3 (2.3) 
83 (64.8) 
9 (7.0) 
24 (18.8) 
Date of second surgery** 
  1/1/2005 – 12/31/2007 
  1/1/2008 – 12/31/2010 
  1/1/2011 – 12/31/2013 
  No second surgery 
 
15 (11.7) 
22 (17.1) 
6 (4.7) 
81 (63.3) 
 
Type of surgery (second 
surgery)** 
  Modified Radical Mastectomy 
  Total or Simple 
  Breast-conserving surgeries (BCS) 
  BCS & Sentinel Node Biopsy 
  BCS & Axillary Node Dissection 
  Revision 
  Other 
  
 
 
0 
4 (3.1) 
0 
0 
3 (2.3) 
7 (5.5) 
29 (22.7) 
Stage of breast cancer 
  Stage I 
  Stage IIa 
  Stage IIb 
  Stage IIIa 
 
50 (39.1) 
41 (32.0) 
22 (17.2) 
15 (11.7) 
*3 missing data 
**4 missing data 
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3.2 HYPOTHESIS 1 
Hypothesis 1: Postmenopausal women with breast cancer self-report (a) higher numbers and (b) 
greater severity of work problems as compared with the control group, at baseline, prior to 
treatment. 
Prior to running t-tests, some data needed transformed, recoded, and/or restructured 
preceding running statistical testing.  Assessment of skewness and missing data were also 
accounted for and noted before statistical analysis and guided proceeding steps. 
T-tests were conducted for each PAOFI subscale to analyze limitations to functioning in 
participants with anastrozole treatment as compared to controls, prior to treatment being 
administered.  Although each PAOFI sub-scale varies in numerical scoring, all sub-scale sum 
scores are understood that the higher scores indicate worse impairment.  Each subscale was 
examined individually and generated independent p-values (Table 7).  There was no significant 
difference in the memory subscale sum scores for anastrozole group (M=8.02, SD=5.39) and 
control group (M=8.25, SD=4.94) conditions; t(256)= -.352, p= .724.  There was no significant 
difference in the language and communication subscale sum scores for anastrozole group 
(M=5.93, SD=5.44) and control group (M=5.80, SD=4.52) conditions; t(256)= .210, p= .691.  
There was no significant difference in the use of hands subscale sum scores for anastrozole 
group (M=1.21, SD=1.37) and control group (M=1.76, SD=1.90) conditions; t(256)= -.2.615, p= 
.051.  There was no significant difference in the sensory/perceptual subscale sum scores for 
anastrozole group (M=.62, SD=1.11) and control group (M=1.06, SD=1.77 conditions; t(256)= -
2.912, p= .081.  There was no significant difference in the higher level of cognitive and 
intellectual functioning subscale sum scores for anastrozole group (M=4.01, SD=4.65) and 
control group (M=3.76, SD=4.50) conditions; t(256)= .443, p= .639. 
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A t-test was conducted for the SF-36–work items sum scores to compare limitations in 
work performance in participants with anastrozole treatment and controls, prior to treatment 
being administered.  Sum scores for work items alone would fall between 7 and 35, with higher 
scores indicating better functioning.  There was a significant difference in the scores for 
anastrozole group (M=26.92, SD=6.62) and control group (M=31.25, SD=5.30) conditions; 
t(258)= -5.86, p= .001 (Table 7).  The results suggest that prior to treatment, there were 
significant differences related to pain between the anastrozole group and the control group.  
A t-test was conducted for the BDI-II sum scores to identify and compare potential 
covariates due to depressive symptoms that may impact results, in participants with anastrozole 
treatment and controls, prior to treatment being administered.  Scores could range from 0-63, 
with higher scores indicating more severe depression.  There was no significant difference in 
the scores for anastrozole group (M= 6.29, SD= 6.62) and control group (M=5.25, SD=5.83) 
conditions; t(269)= 1.37, p= .135 (Table 7).  The results suggest that prior to treatment, there 
were no significant differences related to depression between the anastrozole group and the 
control group.  
A t-test was conducted for the BPI sum scores to identify and compare potential 
covariates due to pain that may impact results, in participants with anastrozole treatment and 
controls, prior to treatment being administered.  Scores could range from 0-70, with higher 
scores indicating more severe pain.  There was a significant difference in the scores for 
anastrozole group (M= 11.73, SD= 16.00) and control group (M=5.21, SD=12.30) conditions; 
t(269)= 3.79, p= .001 (Table 7).  The results suggest that prior to treatment, there were 
significant differences related to pain between the anastrozole group and the control group.  
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A t-test was conducted for the POMS-fatigue/inertia sum scores to identify and compare 
potential covariates due to fatigue that may impact results, in participants with anastrozole 
treatment and controls, prior to treatment being administered. Scores could range from 0-28, 
with higher scores indicating increased fatigue. There was no significant difference in the 
scores for anastrozole group (M= 5.33, SD= 5.18) and control group (M=5.78, SD=5.39) 
conditions; t(259)= -.381, p= .729 (Table 7). The results suggest that prior to treatment, there 
were no significant differences related to fatigue between the anastrozole group and the control 
group. 
Table 7. Comparison of anastrozole and control groups prior to treatment 
 
	   	   Anastrozole 	   	   	   Control 	   	  
Variable, (Total score) n M SD 
	  
n M SD p-value*** 
	  
PAOFI 
Memory (0-54) 123* 8.02 5.39 	   135** 8.25 4.94 .724 
Lang/Comm (0-48) 123* 5.93 5.44 
	  
135** 5.80 4.52 .691 
Use of Hands (0-12) 123* 1.21 1.37 
	  
135** 1.76 1.90 .051 
Sens-Percep (0-18) 123* 0.62 1.11 
	  
135** 1.06 1.77 .081 
Higher Level 
Cogn/Int 
Functioning (0-54) 
 
123* 
 
4.01 
 
4.65 
	    
135** 
 
3.76 
 
4.50 
 
.639 
SF-36 – work items (7-35) 121 26.92 6.62 
	  
139 31.25 5.30 .001 
BDI-II (0-63) 128 6.29 6.62 
	  
143 5.25 5.83 .135 
BPI (0-70) 128 11.73 16.00 
	  
143 5.21 12.30 .001 
POMS–fatigue/inertia (0-28) 122 5.33 5.18 
	  
139 5.78 5.39 .729 *2	  missing	  data	  **1	  missing	  data	  
***Anastrozole group vs. Control group 
 3.3 HYPOTHESIS 2 
Hypothesis 2: Postmenopausal women with breast cancer receiving anastrozole treatment self-
report (a) higher numbers and (b) greater severity of work problems as compared to the control 
group, at pre-treatment, 6 months, and 18 months post initial treatment. 
3.3.1 Patient Assessment of Own Function Inventory (PAOFI) 
A 2 x 3 mixed analysis of variance was performed on the Patient Assessment of Own Function 
Inventory (PAOFI) sub-scales' sum scores, to examine functional limitations as a function of 
time and anastrozole treatment. The within-subjects independent variable was time with 3 levels 
(pre-treatment, 6 months post initial treatment, and 18 months post initial treatment).  The 
between-subjects independent variable was treatment with 2 levels (anastrozole treatment and 
controls with no breast cancer nor treatment).  Prior to running statistics, the data were 
restructured in SPSS to produce workable data for the necessary analysis.  The PAOFI sub-scale 
scores were categorized by six assessment output domains: memory, language and 
communication, use of hands, sensory-perceptual, higher level cognitive and intellectual 
functions.  The participants were measured on the POAFI at pre-treatment, 6 months post 
treatment, and 18 months post treatment.  Assumptions of sphericity, normality, homogeneity of 
variance and covariance and determination of significant differences were established for each 
domain individually and reported respectively.  The means, standard deviations, and standard 
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errors of the anastrozole group’s PAOFI scores are reported in Table 8 and the control group’s 
PAOFI scores are reported in Table 9. 
 
Table 8.  PAOFI Subscales – mean, standard deviation, and standard error of functional limitations by time for 
anastrozole group 
 
Anastrozole Group 
PAOFI subscales 
 
 
n 
 
M 
 
SD 
 
SE 
Memory 
Pre-treatment 
6 mo. 
18 mo. 
42 6.50 4.11 .746 
42 9.14 7.32 .972 
42 9.02 7.14 .949 
Language & Communication 
Pre-treatment 
6 mo. 
18 mo. 
42 4.10 4.01 .675 
42 6.14 5.74 .772 
42 6.50 5.77 .809 
Use of Hands 
Pre-treatment 
6 mo. 
18 mo. 
42 1.14 1.35 .291 
42 1.62 1.79 .294 
42 1.81 1.78 .289 
Sensory-Perception 
Pre-treatment 
6 mo. 
18 mo. 
42 0.50 1.15 .277 
42 1.33 2.17 .295 
42 1.52 2.51 .347 
Higher Level Cognitive &  
Intellectual Functions 
Pre-treatment 
6 mo. 
18 mo. 
41 2.46 3.51 .661 
41 4.29 6.06 .863 
41 5.27 6.85 .913 
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Table 9.  PAOFI Subscales – mean, standard deviation, and standard error of functional limitations by time for 
control group. 
 
Control Group 
PAOFI subscales 
 
 
n 
 
M 
 
SD 
 
SE 
Memory 
Pre-treatment 
6 mo. 
18 mo. 
56 8.32 5.31 .646 
56 7.71 5.41 .842 
56 6.80 5.29 .822 
     
Language & Communication 
Pre-treatment 
6 mo. 
18 mo. 
56 5.40 4.62 .584 
56 4.97 4.34 .668 
56 4.75 4.81 .701 
 
Use of Hands 
Pre-treatment 
6 mo. 
18 mo. 
56 2.25 2.20 .252 
56 1.95 1.99 .255 
56 1.55 1.93 .250 
 
Sensory-Perception 
Pre-treatment 
6 mo. 
18 mo. 
56 1.48 2.16 .240 
56 1.09 1.69 .255 
56 1.13 2.04 .301 
 
Higher Level Cognitive & 
Intellectual Functions 
Pre-treatment 
6 mo. 
18 mo. 
56 3.95 4.69 .566 
56 3.91 5.10 .738 
56 3.79 4.98 .781 
 
 
PAOFI – Memory.  The assumption of homogeneity of covariance was not met, Box’s M 
= 47.47, F(6, 54012.242) = 7.635, p = .001 (α = .001), Mauchly’s W = .962.  Since the data 
violated the assumption, the within-subjects values were reported based on the Greenhouse-
Geisser correction.  Sphericity for within-subjects effects was met, Mauchly’s W = .96, X2 (2) = 
3.63, p = .162.  All other assumptions were met.  There was no significant difference on the 
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PAOFI memory sum scores over the period of time examined within-subjects, F(1.93, 185.05) = 
2.15, p = 0.121, η2 = .022 and there were no significant differences between-subjects, F(1, 96) = 
.343, p = 0.559, η2 = .004.  The result of the PAOFI – Memory sum scores for both groups, over 
time, is displayed in Figure 2.  Note: the time points 1, 2, and 3 represent pre-treatment, 6 
months post-treatment, and 18-months post-treatment respectively.   
 
Figure 2. PAOFI – Memory sum scores at pre-treatment, 6 months, and 18 months 
 
PAOFI - Language & Communication.  The assumption of homogeneity of variance and 
covariance were met, Box’s M = 14.093, F(6, 54012.242) = 2.267, p = .034 (α = .001), 
Mauchly’s W = .971.  Sphericity for within-subjects effects was met, Mauchly’s W = .971, X2 (2) 
= 2.785, p = .248.  The assumption of normality was also met.  All other assumptions were 
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met.  There was no significant difference on the PAOFI language and communication sum 
scores over the period of time examined within-subjects, F(2, 192) = 2.704, p = 0.069, η2 = 
0.027, and there was no significant difference between-subjects, F(1, 96) = .382, p = 0.538, η2 = 
0.004.  The result of the PAOFI – Language & Communication sum scores for both groups, over 
time, is displayed in Figure 3.  Note: the time points 1, 2, and 3 represent pre-treatment, 6 
months post-treatment, and 18-months post-treatment respectively. 
 
Figure 3. PAOFI – Language & Communication sum scores at pre-treatment, 6 months, and 18 months 
 
PAOFI - Use of Hands.  The assumption of homogeneity of variance and covariance 
were met, Box’s M = 11.987, F(6, 54012.242) = 1.928, p = .072 (α = .001), Mauchly’s W = .982.  
Sphericity for within-subjects effects was met, Mauchly’s W = .982, X2 (2) = 1.753, p = 
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.416.  The assumption of normality was also met.  All other assumptions were met.  There was 
no significant difference on the PAOFI use of hands sum scores over the period of time 
examined within-subjects, F(2, 192) = .167, p = 0.846, η2 = .002, and no significant difference 
between-subjects, F(1, 96) = 1.531, p = 0.219, η2 = .016.  The result of the PAOFI – Use of 
Hands sum scores for both groups, over time, is displayed in Figure 4.  Note: the time points 1, 
2, and 3 represent pre-treatment, 6 months post-treatment, and 18-months post-treatment 
respectively. 
 
Figure 4. PAOFI – Use of Hands sum scores at pre-treatment, 6 months, and 18 months 
 
PAOFI - Sensory-Perceptual.  The assumption of homogeneity of covariance was not 
met, Box’s M = 36.752, F(6, 54012.242) = 5.911, p = .001 (α = .001), Mauchly’s W = .942.  
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Since the data violated the assumption, the within-subjects values were reported based on the 
Greenhouse-Geisser correction.  Sphericity for within-subjects effects was met, Mauchly’s W = 
.942, X2 (2) = 5.702, p = .058. All other assumptions were met.  There was no significant 
difference on the PAOFI sensory-perceptual sum scores over the period of time examined 
within-subjects, F(1.89, 181.43) = 1.609, p = .204, η2 = .016, and no significant differences 
between-subjects, F(1, 96) = .108, p = .743, η2 = .001.  The result of the PAOFI – Sensory-
Perceptual sum scores for both groups, over time, is displayed in Figure 5.  Note: the time points 
1, 2, and 3 represent pre-treatment, 6 months post-treatment, and 18-months post-treatment 
respectively. 
 
Figure 5. PAOFI – Sensory-Perceptual sum scores at pre-treatment, 6 months, and 18 months 
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PAOFI - Higher Level of Cognitive & Intellectual Function.  The assumption of 
homogeneity of covariance was not met, Box’s M = 35.610, F(6, 51137.465) = 5.724, p = .001 
(α = .001), Mauchly’s W = .956. Since the data violated the assumption, the within-subjects 
values were reported based on the Greenhouse-Geisser correction.  Sphericity for within-subjects 
effects was met, Mauchly’s W = .956, X2 (2) = 4.269, p = .118.  The assumption of normality 
was also met.  All other assumptions were met.  There was a significant difference on the PAOFI 
higher level of cognitive & intellectual function sum scores over the period of time examined 
within-subjects, F(1.92, 181.92) = 4.639, p = .012, η2 = .047.  There were no significant 
differences determined between-subjects, F(1, 95) = .018, p = .894, η2 = .001. 
Post hoc pairwise comparisons were performed using the Bonferroni adjustment to find 
the pattern of differences of functional limitations of the anastrozole group overtime.  The 
participants reported significantly more functional limitations at 18 months post initial treatment 
as compared to before beginning treatment, p = .012.  There were no other significant 
differences.  The result of the PAOFI – Higher Level of Cognitive & Intellectual Function sum 
scores for both groups, over time, is displayed in Figure 6.  Note: the time points 1, 2, and 3 
represent pre-treatment, 6 months post-treatment, and 18-months post-treatment respectively. 
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 Figure 6. PAOFI – Higher Level of Cognitive & Intellectual Function sum scores at pre-treatment, 6 
months, and 18 months 
3.3.2 Medical Outcomes Study Short Form 36 Health Survey (SF-36) work items 
A 2 x 3 mixed analysis of variance was performed on the Medical Outcomes Study Short Form 
36 Health Survey (SF-36) work items sum scores, to examine work problems as a function of 
time and anastrozole treatment.  The within-subjects independent variable was time with 3 levels 
(pre-treatment, 6 months post initial treatment, and 18 months post initial treatment).  The 
between-subjects independent variable was treatment with 2 levels (anastrozole treatment and 
controls with no breast cancer nor treatment). Prior to running statistics, the data was restructured 
 47 
in SPSS to produce workable data for the necessary analysis.  The participants were measured on 
the SF-36–work items at pre-treatment, 6 months post treatment, and 18 months post treatment.  
The means, standard deviations, and standard errors of the anastrozole group and control group’s 
SF-36–work items scores were reported in Table 10.   
The assumption of homogeneity of variance and covariance were met, Box’s M = 21.463, 
F(6, 56884.708) = 3.454, p = .002 (α = .001), Mauchly’s W = .921.  Sphericity for within-
subjects effects was not met, Mauchly’s W = .921, X2 (2) = 7.86, p = .020.  Since the data 
violated the assumption, the within-subjects values were reported based on the Greenhouse-
Geisser correction.  All other assumptions were met.  There was no significant difference on the 
SF-36–work items scores over the period of time examined within-subjects, F(1.854, 179.864) = 
1.20, p = .301, η2 = .012, but there was a significant difference between-subjects, F(1, 97) = 
12.205, p = .001, η2 = .112. 
 
Table 10.  SF-36 work items – mean, standard deviation, and standard error of work problems by time for 
anastrozole group and control group. 
SF-36 work items n M SD SE 
Anastrozole Group 
Pre-treatment 
6 mo. 
18 mo. 
43 26.79 6.15 .939 
43 28.00 6.72 1.024 
43 28.53 7.02 1.070 
Control Group  
Pre-treatment 
6 mo. 
18 mo. 
56 31.36 5.16 .689 
56 31.20 5.06 .677 
56 31.21 4.67 .624 
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3.4 HYPOTHESIS 3 
Hypothesis 3: Postmenopausal women with breast cancer receiving anastrozole will self-report 
(a) higher numbers and (b) greater severity of work problems over time. 
3.4.1 Follow-up Health Questionnaire 
Qualitative analysis of repeated measures was used to study frequency and severity of work 
problems, self-reported by the participants as results of the Follow-up Health Questionnaire.  
Results were examined at 6 months and 18 months post initial anastrozole treatment. The 
Follow-up Health Questionnaire included 6 “yes” or “no” questions, each requesting open-ended 
detail when appropriate.  Of the six items, the results from the question, “Have you had any other 
significant changes in life since our last meeting,” were found to be most applicable for this 
study and therefore were incorporated in the results for hypothesis #3.  As the other 
questionnaire items mostly pertained to health related concerns, this question remained open for 
potential reports of work related issues.  Only the anastrozole group’s results were assessed, in 
line with the aims of the hypothesis.  Multiple participants reported more than one change; 
therefore change 1 and change 2 define potentially two changes for several participants. Not all 
participants who reported one change also reported a second change.  Not all changes related to 
work and not all participants identified a significant life change since the previous meeting.   
The original data of reported changes were listed verbatim by the participants’ response 
to the open-ended questions.  For this study, the responses were then examined individually to 
identify responses related to work.  At that point, each response was then categorized into work-
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related groupings or variables that were similar in nature, such as a positive work change (i.e. 
new job) or negative work change (i.e. lost job), as described in table 11. 
At 6 months, 73 participants who received anastrozole treatment completed the 
questionnaire.  Of those individuals 38.4% (n= 28) reported that they had experienced a 
significant life change and 61.6% (n= 45) reported to have not experienced a significant life 
change.  At 18 months post anastrozole treatment, 45 participants completed the questionnaire 
with 42.2% (n= 19) responding yes and 57.8% (n= 26) responding no to experiencing a 
significant life change.  Furthermore, only the open-ended, self-reported responses provided by 
the subjects were considered in analysis.  Both positive and negative reports of work related 
situations were studied.  The responses were categorized by common themes and included: (a) 
working again/new job/additional job responsibilities/ working two jobs to help finances; (b) 
retired/semi-retired (spouse and/or participant); (c) had to decrease work hours due to fatigue 
secondary to treatment; (d) lost job/stress at work/looking for new job/gave up job, can’t do 
anymore/work hours cut back/less pay due to shift change.  Table 11 reflects the reported 
changes, related to work, by number and percentage at 6 months and 18 months.  The (%) 
represents the percent of work-related changes out of the total number of yes responses in that 
time domain and change report category (change 1 or 2).   
The total number of individuals who stated that yes they had experienced a significant life 
change, are represented at the bottom of table 11.  The highest number of reported changes in 
work is 4 total changes, at both 6 month and 18 months.  In the case of this study, the changes 
are determined to be positive as the individuals reported working again, new job, additional job 
responsibilities, or working two jobs, which assumes more cognitive and physical demands, 
therefore rejecting the hypothesis that reports of work problems would increase overtime. 
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Table 11.  Changes Reported on Follow-up Health Questionnaire – Anastrozole Group 
  6 months   18 months 
 Change 1  Change 2  Change 1  Change 2 
Work-related Variables n (%) 
 
n (%)   n (%) 
 
n (%) 
Working again/new job/additional job 
responsibilities/working two jobs to help 
finances 
4 (5.5)   1 (1.4)  4 (8.9)   1 (0.8) 
 
           
Retired/semi-retired (spouse and/or 
participant) 
1 (1.4)  0 (0.0)  2 (4.4)  1 (0.8) 
 
           
Had to decrease work hours due to 
fatigue secondary to treatment 
0 (0.0)  0 (0.0)  0 (0.0)  1 (0.8) 
 
           
Lost job/stress at work/looking for new 
job/gave up job can`t do anymore/work 
hours cut back/less pay due to shift 
change 
2 (2.7)   1 (1.4)   2 (4.4)   1 (0.8) 
  
 Total work-related changes reported            7          2              8  4  
Total life changes reported 28 
  
7 
  
19 
  
9 
  
3.5 EXPLORATORY ANALYSIS 
3.5.1 Brief Pain Inventory (BPI) 
Given the results of the hypotheses, specifically hypothesis 1, pain was identified as a 
confounding variable as the anastrozole and control groups were significantly different on the 
BPI measure at baseline.  Women with breast cancer taking aromatase inhibitors have been 
documented experiencing higher incidences of joint pain, as opposed to some other types of 
treatment (Crew et al., 2007).  Given that pain may have been a confounding variable throughout 
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the study, exploratory analysis was completed to investigate whether pain remained constant or 
changed for the groups after treatment. 
A 2 x 3 mixed analysis of variance was performed on the Brief Pain Inventory (BPI) sum 
scores, to examine reported pain as a function of time and anastrozole treatment.  The within-
subjects independent variable was time with 3 levels (pre-treatment, 6 months post initial 
treatment, and 18 months post initial treatment).  The between-subjects independent variable was 
treatment with 2 levels (anastrozole treatment and controls with no breast cancer nor treatment). 
Prior to running statistics, the data was restructured in SPSS to produce workable data for the 
necessary analysis.  The participants were measured on the BPI at pre-treatment, 6 months post 
treatment, and 18 months post treatment.  The means, standard deviations, and standard errors of 
the anastrozole group and control group’s BPI scores were reported in Table 12.   
The assumption of homogeneity of variance and covariance were met, Box’s M = 8.025, 
F(6, 59126.136) = 1.293, p = .256 (α = .001), Mauchly’s W = .989.  Sphericity for within-
subjects effects was also met, Mauchly’s W = .989, X2 (2) = 1.133, p = .567. All other 
assumptions were met.  There was no significant difference on the BPI scores over the period of 
time examined within-subjects, F(2, 204) = .650, p = .523, η2 = .006, but there was a significant 
difference between-subjects, F(1, 102) = 5.941, p = .017, η2 = .055.  This difference is displayed 
graphically in Figure 7.  Note: time points 1, 2, and 3 represent pre-treatment, 6 months post-
treatment, and 18 months post-treatment, respectively.   
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Table 12.  BPI – mean, standard deviation, and standard error of pain by time for anastrozole group and control 
group. 
BPI n M SD SE 
Anastrozole Group 
Pre-treatment 
6 mo. 
18 mo. 
44 11.14 15.05 2.28 
44 12.71 15.94 2.44 
44 15.91 17.47 2.28 
Control Group  
Pre-treatment 
6 mo. 
18 mo. 
60 7.17 15.22 1.96 
60 8.18 16.34 2.09 
60 5.38 13.18 1.95 
 
 
 
Figure 7. BPI sum scores at pre-treatment, 6 months, and 18 months 
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4.0  DISCUSSION 
Self-reported data provides perspective of the individual experiencing the condition and the 
individual’s understanding of resulting manifestations due to the condition.  This study aimed to 
examine self-reported work problems after anastrozole treatment in postmenopausal women with 
breast cancer.  In this study it was found that overall, the anastrozole group reported more work 
problems than the control group overtime.  Pain emerged as a confounding variable that supports 
reason for further investigation of the effects and role of pain due to breast cancer and/or 
treatment, specifically as it pertains to work performance. 
4.1 HYPOTHESIS 1 
 
Hypothesis 1 proposed that postmenopausal women with breast cancer self-report (a) higher 
numbers and (b) greater severity of work problems as compared with the control group, at 
baseline, prior to treatment.   
The PAOFI subscales, SF-36 –work items, BDI-II, BPI, and POMS-fatigue/inertia sum 
scores were evaluated to investigate the participants’ perceived limitations to their individual 
ability to function.  Among all five subscales of the PAOFI, there were no significant differences 
between the breast cancer (anastrozole) group and the control group, rejecting the null hypothesis 
 54 
for this measure and proposing that statistically there were no major differences between the 
amount and severity of functional limitations between the groups at baseline for that measure.  
The SF-36–work items supported the hypothesis and showed a significant difference between the 
anastrozole and control groups (p< .001).  The means of the groups displayed overall lower 
scores for the anastozole group, which suggests that the women with breast cancer reported more 
limitations to functional ability related to work.  Limitations for the anastrozole group at baseline 
may be due to effects of the breast cancer such as symptoms of pain, nausea, or changes in body 
function, or result of surgery. 
To consider other physiological factors that may affect work performance, the BDI-II, 
POMS-fatigue/inertia, and BPI were used to uncover any potential covariates or confounding 
factors at baseline. The BDI-II and the POMS-fatigue/inertia measures produced no significant 
results and rejected the hypothesis in the case of these two measures.  Alternatively, the results of 
the BPI produced a significant difference (p< .001), and by comparing groups’ means implies 
that women with breast cancer report more pain compared to controls, prior to administration of 
treatment (Table 7).  The report of pain seemed rational as breast cancer has tendency to be 
painful for many women.  For this reason, the exploratory analysis of BPI data overtime was 
later run to investigate potential increases of pain overtime and the pain differences between the 
groups overtime (see below in section 4.4). 
 To address hypothesis 1 in summary, at baseline prior to anastrozole treatment, women 
with breast cancer reported higher numbers of work problems and greater physical pain than 
controls.  Unexpectedly though, while women with breast cancer reported more functional 
problems with working, they did not significantly differ from the control group on reports of 
individual assessment of their own functioning (memory, language and communication, use of 
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hands, sensory-perceptual ability, higher level of cognitive and intellectual functioning), as 
assessed by the PAOFI subscales.  Additionally, based on findings, women with breast cancer 
and controls had similar levels of depression and fatigue prior to treatment. 
 As mentioned previously, women treated for breast cancer, in various positions and types 
of occupations, commonly experience job loss, demotion, unwanted changes in tasks, problems 
with the employer and co-workers, personal changes in attitudes to work and diminished 
physical capacity (Brisson et al., 1999).  Multiple factors may be contributing to the women’s 
perceptions of work problems.  The PAOFI is a self-report tool.  An objective measure of 
physical and cognitive abilities or limitations to function would properly supplement the PAOFI 
to confirm accurate report of limitations.  Also, attitudes or possible discrimination from others, 
not directly captured in the measures used in this study, have potential to highly impact work 
performance and work satisfaction.  Furthermore, an individual’s meaning of the value of work 
may also be changed as values often shift and other life factors take priority when cancer is 
diagnosed.  Work may not be of the greatest importance currently, therefore possible lack of 
effort at work and chance of an increase in the individual’s perceived work problems.  
4.2 HYPOTHESIS 2 
 
Hypothesis 2 proposed that postmenopausal women with breast cancer receiving anastrozole 
treatment self-report (a) higher numbers and (b) greater severity of work problems as compared 
to the control group, at pre-treatment, 6 months, and 18 months post initial treatment. 
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The PAOFI subscales data and SF-36 data were independently analyzed to examine 
functional limitations (PAOFI) and work problems (SF-36), to identify potential variances 
within-subjects and between-subjects.  Analytical testing revealed that there were no significant 
differences within-subjects nor between-subjects for the PAOFI subscale measures of memory, 
language and communication, and sensory-perceptual functioning.  A significant difference was 
identified within-subjects on the PAOFI higher level of cognitive & intellectual function subscale 
(p= .012); there was no significant difference between-subjects.  Further analysis recognized that 
the greatest difference in report of functional limitations was between baseline and 18 months 
post anastrozole treatment.  This implies that the cognitive/intellectual effects of treatment 
diminish overtime.  While some studies support cognitive impairment due to treatment, the work 
of Buwalda and Schagen (2013) suggests that there is little evidence that aromatase inhibitors 
have a lasting detrimental effect on cognitive performance in breast cancer patients.  
The SF-36–work items results demonstrated the presence of significant differences 
between the anastrozole group and the control group overtime but not within-subjects.  The 
anastrozole group reported more physical and emotional problems related to work.  These 
findings are supported by a substantial amount of literature on work-related issues hypothesized 
to be due to breast cancer treatment (Villaverde et al., 2008; Moran, Short, & Hollenbeak, 2011; 
Brisson et al., 1999)  
The SF-36–work items results supported hypothesis 2, indicating that postmenopausal 
women with breast cancer do report higher frequencies of work problems over time as compared 
to the control group (p= .001).  The within-subjects results produced by the PAOFI higher level 
of cognitive & intellectual function subscale may better support hypothesis 3 as it simply 
addresses women experiencing greater functional limitations over time as compared to 
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themselves at different time points.  Cognitive limitations due to anastrozole treatment were 
studied by Calvio, Peugeot, Bruns, Todd, and Feuerstein (2010) and results of the study were 
analogous with the results produced by the SF-36 measure.  Interestingly, their discussion 
included that fatigue and job stress presented the strongest correlation of work problems.  
Fatigue due to anastrozole treatment may be an avenue of study that can contribute to the overall 
understanding of the effects of anastrozole but were not directly examined in this study. 
4.3 HYPOTHESIS 3 
 
Hypothesis 3 proposed that postmenopausal women with breast cancer will self-report (a) higher 
numbers and (b) greater severity of work problems over time. 
The Follow-up Health Questionnaire was implemented to qualitatively assess work 
problems overtime in just the anastrozole group, in addition to other open-ended comments, both 
positive and negative, about work that the participants provided.  While the PAOFI higher level 
of cognitive & intellectual function subscale indirectly supports hypothesis 3 by addressing 
limitations to function, it was determined that there is not sufficient enough evidence to strongly 
support hypothesis 3.  Only minimal numbers of reported work problems were reported in the 
data, and were too small to analyze statistically.  Nonetheless, the qualitative data shows  (Table 
10) that while both positive and negative changes occurred, majority of changes were negative or 
unfavorable, assuming that the loss of a job or stress at work would be considered unfavorable.  
Negative work changes have potential of being the result of the effects and symptoms of breast 
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cancer or its treatment, attitudes or discrimination of co-workers, supervisors, and employers, or 
personal factors of the individual coping with the condition. 
4.4 EXPLORATORY ANALYSIS - PAIN 
Pain emerged as a potential confounding variable at baseline and between subjects overtime.  
The anastrozole group reported significantly higher levels of pain throughout the study as 
compared to the control group.  These findings suggest, similarly to the literature, that pain is 
commonly a side effect of aromatase inhibitor treatment and/or a symptom of breast cancer.  
More specific to the current study, with the understanding that pain was present throughout the 
data collection, did the effects of pain compromise other variables in the study such as perception 
of work limitations, fatigue, or cognitive functioning?  Naturally, with increased pain, humans 
feel less physically capable as opposed to when there is less pain present.  Further studies are 
recommended for the degree of pain caused by breast cancer and aromatase inhibitor treatments, 
pain related to work performance, and the effects of pain on self-report assessments.  
4.5 LIMITATIONS 
In this study self-reported data was used for all measures.  Obvious concerns of poor validity and 
reliability were taken into consideration upon data analysis.  Although self-reported information 
is of great value, implementing an objective data measure in addition to the current measures 
would be ideal to compliment the subjective information the patients provided. 
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Although the design of the study succeeded in providing knowledge of frequency of work 
performance limitations, once the data was being assessed, it was clear that the measures failed 
to capture the level of severity of the work problems (example: job loss is more severe than a 
demotion).  The measures posed a problem in gathering this data because there was a lack of data 
and specific questions to directly reflect the severity component.  Varieties of work problems 
were lumped together in the data and not available to distinguish between each type of work 
problem.  To correct this, a measure would either be researched or developed to adjust and 
directly assess work content and intensity, ranking work changes or problems on a well-
developed and standardized severity scale. 
Pain may also be moderating perception of function and self-report data, potentially 
interfering with reliable self-report, and should be adjusted for in future studies.  The 
combination of poor reliability of self-reported data and affective factors may compound the 
unreliability and potentially negate the use of self-reported data as a reliable measure.   
On the Follow-up Health Questionnaire, in addition to the low number of reported work 
problems, ranking the severity of work problems was determined to be unwarranted due to 
insignificant numbers and lack of data to directly reflect the severity component.  Simply based 
on numbers, the work changes by category for the anastrozole group overall presented to be 
more positive than negative as double the amount of women reported a positive work increase as 
opposed to the other category of work changes who reported work loss.  A more robust tool 
would be necessary to capture the true effect. 
There are significant differences between groups in work problems for the SF-36–work 
items measure.  Equally, it was expected that the PAOFI would also present functional 
limitations, as limitations to function would likely be the cause of the work problem.   Unless 
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however, this would occur if the work problems were due to another outstanding factor that a 
significant number of women in the anastrozole group were experiencing, not directly associated 
with functional abilities captured by the PAOFI.  Such impacts may be the typical aging process, 
economic situation, attitudes toward women with breast cancer or breast cancer survivors.  This 
would imply different measures would be more appropriate depending on the identification of 
the specific factors potentially affecting the study outcomes. Further investigation and studies 
would be recommended.   
Furthermore, the study was limited by the demographic disposition of the sample.  The 
sample consisted of predominantly white American women and a portion of African American 
women.  No other racial or ethnic groups were represented.  A more diverse demographic 
population, specifically racial/ethnic diversity would be ideal for a normally distributed sample.   
4.6 FUTURE STUDIES 
The purpose of this study was to examine the effects of the anastrozole breast cancer treatment, 
as it relates to the individuals’ abilities to function at work.  Ideal next steps in research would 
include identifying specific work problems to promote analyzing the impact in specific work 
contexts in future studies.  Job analysis and workplace analysis would improve the understanding 
of job and workplace demands and how the individual can function optimally in that role and 
what supports may be necessary for success.  This would enhance the current knowledge of the 
impact of anastrozole treatment on work performance. 
Agreeing with Steiner, et al. (2004), it would be beneficial to develop a model to properly 
assess work problems due to breast cancer treatment.  Potentially taking a closer look at 
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contextual factors including personal factors such as ethnicity and socioeconomic status, 
affective functioning, coping strategies and environmental factors such as support system, 
economic impact, and attitudes. 
Additionally, observational studies of work performance including job analysis and 
vocational assessment prior to breast cancer treatment and post treatment may render more valid 
outcomes and initiate ideas for intervention and possibly work accommodations if necessary, to 
mitigate the potential negative impacts on work performance.   
4.7 IMPLICATIONS FOR HEALTH & REHABILITATION PROFESSIONALS 
Analyzing the impact of anastrozole treatment in specific work contexts will supplement the 
current available literature.  The results of this study suggest that multiple factors may be 
affecting work performance in addition to anastrozole treatment, specifically pain.  
Consideration of pain management, therapy, or alternative breast cancer treatment should be 
thoroughly discussed prior to treatment decision-making.   
Knowing that more individuals with breast cancer are surviving and are continuing to 
work or returning to work, in addition to being aware that treatment effects and residual 
symptoms are often present, this population is likely in need of vocational rehabilitation support 
and services.  While breast cancer does not have an instant cure, these women should likewise 
not be expected to return to their routine lives and work at optimal performance.  Counseling and 
vocational services would be advantageous for this population to utilize as returning to work is a 
process and requires adjustment.  A rehabilitation counselor could provide knowledge of and 
advocacy for work accommodations and modifications to assist the individual in working toward 
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successful function at work.  As many aspects of breast cancer and its treatments are disabling, it 
would be worthwhile to advocate for funding and support to view cancer as a disability.   
Health and rehabilitation professionals are recommended to evaluate the needs of the 
individual with breast cancer, especially as it pertains to treatment options, in a broader 
perspective by adopting a holistic approach and thoroughly assessing the contextual factors of 
the individual including personal, social, and environmental factors, including value of work and 
work performance.  Supplemental information such as information provided by the individual’s 
support system, may be incorporated to gather a more global understanding of function and 
impacts due to treatment or other factors.  
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5.0  CONCLUSION 
As more women are living longer after breast cancer treatment and are returning to or 
maintaining jobs and careers, assessing impacts of breast cancer treatments on work performance 
is critical to guide future treatment decision making and rehabilitative interventions.  Limitations 
in higher-level cognitive and intellectual functions were identified to be affected by the 
anastrozole treatment, but no other functional limitations exhibited significant changes.  Results 
of this study suggest that anastrozole treatment may decrease work performance or increase work 
problems.  As work performance would be assumed to be dictated by functional abilities, it 
remains unclear if anaztrozole treatment is directly impacting work limitations or if it may be 
working in conjunction with additional contextual factors, such as external barrios, or personal 
factors.  Pain emerged as a confounding variable throughout the study, as the anastrozole group 
consistently reported more pain than the control group.    
Through future clinical practice and research, if significant patterns of additional factors 
are identified, it may prove beneficial to return to this research and correct for covariates or other 
impacting factors and incorporate additional measures that objectify work performance 
outcomes.  Future studies are needed to explore work performance related to anastrozole 
treatment.  Additional research findings may update current information related to function at 
work, to add to the ICF core sets for breast cancer, ultimately assisting in the treatment decision 
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making, vocational rehabilitation service delivery and improving quality of life and work 
satisfaction of breast cancer survivors. 
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APPENDIX A 
STUDY DESIGN GRAPHICAL REPRESENTATION 
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